Sign In
Buy DNLI
$19.66
+0.310 (+1.60%)
At Close: Jun 03, 2026
Denali Therapeutics: 'Strong Buy' On AVLAYAH Approval And End Of 2026 FTD-GRN Data
07:54am, Wednesday, 27'th May 2026
Denali Therapeutics (DNLI) maintains a "Strong Buy" rating following FDA Accelerated Approval of AVLAYAH for Hunter Syndrome and robust pipeline momentum. Company's DNL593 for FTD-GRN is differentiate
Denali Stock Dips as Biogen-Partnered Parkinson's Disease Study Fails
01:15pm, Friday, 22'nd May 2026
DNLI sinks after BIIB122 failed a mid-stage Parkinson's study, prompting Denali and Biogen to halt development in idiopathic cases.
Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval
02:23pm, Monday, 18'th May 2026
This biotech develops therapies for neurodegenerative diseases, advancing a broad pipeline through strategic pharmaceutical partnerships.
Denali Therapeutics Says AVLAYAH Launch Ahead of Expectations After Hunter Syndrome Approval
06:08am, Saturday, 16'th May 2026
Denali Therapeutics NASDAQ: DNLI is seeing early commercial interest for its first approved drug, AVLAYAH, following its March 24 accelerated approval for Hunter syndrome, Chief Operating Officer and
Denali Therapeutics Inc. (DNLI) Presents at Bank of America Global Healthcare Conference 2026 Transcript
10:00pm, Tuesday, 12'th May 2026
Denali Therapeutics Inc. (DNLI) Presents at Bank of America Global Healthcare Conference 2026 Transcript
DNLI Q1 Loss Narrower Than Expected, Avlayah Approval Boosts Prospects
01:41pm, Friday, 08'th May 2026
Denali narrows its Q1 loss and gains FDA approval for Avlayah, the first new Hunter syndrome treatment option in nearly 20 years.
Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
04:01pm, Thursday, 07'th May 2026
SOUTH SAN FRANCISCO, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the first quarter ended March 31, 2026, and provided business
Privium Fund Opens $5.07 Million Denali Stake Ahead of FDA Drug Approval
04:33pm, Tuesday, 05'th May 2026
This biotech company develops therapies for neurodegenerative and rare diseases, supported by clinical assets and pharma collaborations.
Denali: The First Commercial Validation Of The Blood-Brain Barrier Platform
12:13am, Sunday, 03'rd May 2026
Denali Therapeutics has transitioned from a speculative platform to a commercial-stage rare disease company with FDA approval of AVLAYAH for Hunter syndrome. DNLI's TransportVehicle technology enables
DNLI Gains 25.4% Year to Date: Should You Buy, Sell or Hold the Stock?
02:40pm, Friday, 17'th Apr 2026
DNLI secures FDA nod for Avlayah, a first-in-decades Hunter syndrome therapy, but pipeline risks and Takedas exit complicate the outlook.
Denali Stock Falls as Partner Takeda Ends Collaboration Deal
03:31pm, Tuesday, 07'th Apr 2026
DNLI's shares decline after Takeda exits DNL593 partnership, leaving Denali to fully control and fund the therapy as it advances studies and plans 2026 data release.
Takeda Exits Dementia Drug Partnership With Denali Therapeutics - Here's Why
01:26pm, Monday, 06'th Apr 2026
Takeda on Friday notified Denali Therapeutics regarding the termination of their collaboration agreement to co-develop DNL593, a progranulin replacement therapy for frontotemporal dementia.
Capricorn Fund Managers Ltd Acquires New Position in Denali Therapeutics Inc. $DNLI
04:59am, Monday, 06'th Apr 2026
Capricorn Fund Managers Ltd acquired a new stake in Denali Therapeutics Inc. (NASDAQ: DNLI) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange C
SG Americas Securities LLC Increases Stock Position in Denali Therapeutics Inc. $DNLI
04:47am, Sunday, 05'th Apr 2026
SG Americas Securities LLC boosted its holdings in Denali Therapeutics Inc. (NASDAQ: DNLI) by 291.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Com
Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Average Rating of “Moderate Buy” from Analysts
02:35am, Sunday, 05'th Apr 2026
Denali Therapeutics Inc. (NASDAQ: DNLI - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the sixteen ratings firms that are covering the stock, MarketBeat.com reports.
